Australian scientists suggest going slow on AstraZeneca vaccine as infections fall

Published: Updated:
Enable Read mode
100% Font Size

Some Australian scientists have proposed delaying mass inoculation using AstraZeneca’s COVID-19 vaccine with a view to considering a different shot instead.

For more coronavirus news, visit our dedicated page.

Questions surrounding the vaccine in Australia, which recorded just one new local case of the coronavirus on Wednesday, have cast a cloud over its immunization plans, with 53 million doses of the AstraZeneca jab already on order.

For all the latest headlines follow our Google News channel online or via the app

Experts cited data showing the AstraZeneca jab had 62 percent efficacy compared with over 90 percent for a vaccine developed by Pfizer and its partner BioNTech.

Read more:

Coronavirus: Netherlands launches COVID-19 mass testing program amid new strain fears

Malaysia will only go ahead with Sinovac vaccine on basis of clinical trial data

Coronavirus: Putin orders Russian officials to begin mass COVID-19 vaccinations next

“The question is really whether it (AstraZeneca) is able to provide herd immunity. We are playing a long game here. We don’t know how long that will take,” said Professor Stephen Turner, president of the Australian and New Zealand Society for Immunology (ASI).

Turner added that the government must pivot towards getting more of the Moderna and Pfizer vaccines.

Earlier, he told the Sydney Morning Herald that the AstraZeneca vaccine is not one “I would be deploying widely because of that lower efficacy.”

In a statement, the ASI said Turner was speaking as an expert in immunology and that the body did not advocate a pause to the rollout as widely reported by local media.

Australia has agreed to buy 10 million doses of the Pfizer vaccine, though neither AstraZeneca nor Pfizer have approval from the country’s drug regulator, the Therapeutic Goods Administration (TGA).

AstraZeneca did not immediately respond to an email request for comment.

Its vaccine is approved in Britain, India and Argentina and is under review by several other countries including South Korea and Brazil.

‘Effective, safe, high quality’

Australia’s chief medical officer, Paul Kelly, attempted to address concerns around the efficacy of the AstraZeneca vaccine, calling it “effective”, “safe” and “high quality”.

“The great advantage of the AstraZeneca vaccine is it’s being made here in Australia,” Kelly said. “It will be available as soon as the TGA gives its tick, which we expect that it will in February.”

Kelly said Australia would have more data by February as well as “real-world information” coming from London, which has already rolled out the vaccine.

Australia has been more successful than many other countries in managing the pandemic, with total infections in the country of 25 million people at about 28,600, with 909 deaths.

Its success is largely attributable to closed borders and widespread compliance with social-distancing rules, along with aggressive testing and tracing programs.

Given the low case numbers and community transmission rates, some experts say Australia could afford to wait for a more effective vaccine.

“The government needs to be flexible in its rollout decisions once we have a better understanding of the efficacy of the other vaccines,” said Adrian Esterman, chair of Biostatistics and Epidemiology at the University of South Australia.

Australia recorded one new local coronavirus case in its most populous state of New South Wales on Wednesday.

In Queensland, hundreds of hotel quarantine guests were forced to restart their isolation after a handful of cases in the facility were linked to the highly contagious UK virus strain.

Top Content Trending